Please wait while the formulary information is being retrieved.
MARQIBO (VINCRISTINE SULFATE LIPOSOMAL)
- Philadelphia chromosome-negative b-cell ALL
5 mg/31 mL (0.16 mg/mL) (Final Conc.) intravenous kit
- Infuse 2.25 mg/m2 over 60 minute(s) by intravenous route every 7 days
Philadelphia chromosome-negative b-cell ALL
- Infuse 2.25 mg/m2 over 60 minute(s) by intravenous route every 7 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- Digox
- digoxin
- Lanoxin
- Charcot-marie-tooth disease
- Lactating mother
Contraindicated
- Bacterial infection
- Neuromuscular disease
- Opportunistic fungal infection
- Opportunistic viral infection
- Pregnancy
- Protozoal infection
- Urate renal calculi
Severe
Moderate
- Biliary obstruction
- Chronic pulmonary disease
- Hyperbilirubinemia
- Hyperuricemia
- Leukopenia
- Peripheral motor neuropathy
- Peripheral neuropathy
- Polyneuropathy
- Severe hepatic disease
MARQIBO (VINCRISTINE SULFATE LIPOSOMAL)
- Philadelphia chromosome-negative b-cell ALL
- Anemia
- CNS toxicity
- Neutropenic disorder
- Thrombocytopenic disorder
- Anorexia
- Constipation
- Diarrhea
- Fatigue
- Fever
- Insomnia
- Nausea
- Peripheral neuropathy
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Acute respiratory insufficiency
- Ileus
- Pneumonia
- Abdominal pain with cramps
- Hypotension
- Muscle weakness
- Pain
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cardiac arrest
- Drug-induced hepatitis
- Extravasation injury
Less Severe
- Orthostatic hypotension
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Vincristine Liposome
No safety and efficacy established in pediatrics.
- 1 Day – 18 Years
- No safety and efficacy established in pediatrics.
Vincristine
- Severity Level:
D
- Additional Notes:
Contraindicated
Vincristine
Insufficient data available. Potential severe adverse effects.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient data available. Potential severe adverse effects. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This drug is to be given by injection only into a vein. It must not be injected into the spine or into other areas of the body since fatal reactions have occurred. Vincristine liposomal injection is different than vincristine injection. The two drugs have different dosage recommendations.
| Philadelphia chromosome-negative b-cell ALL | |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
Formulary Reference Tool